We highlight the technology and scientific advancements of BIO Digital participating companies and BIO member companies in our Biotechnology: Beyond Imagination series. Our next feature focuses on Sangamo Therapeutics and its work with gene therapy for a potential treatment for Alzheimer’s patients.
Beyond Imagination Member Spotlight: Sangamo Therapeutics
A pioneer in genomic medicine, Sangamo Therapeutics uses four types of technologies – gene therapy, cell therapy, in vivo genome editing and in vivo genome regulation – to focus on the genetic causes of disease, such as hemophilia, Fabry and Alzheimer’s.
The company recently announced a collaboration with Biogen to develop ST-501, a gene regulation therapy for Alzheimer’s disease and other tauopathies, using Sangamo’s zinc finger protein technology...
